Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982747 | 0.84 | RECQL (0.59) | USP2SMN1; SMN2RECQLPIK3CASETD7 | |
| SCHEMBL12021701 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL315706 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL12021512 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL12090135 | 0.80 | MEN1 (0.50) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA | |
| SCHEMBL16616 | 0.77 | CA12 (0.41) | PIK3CA | |
| SCHEMBL12078425 | 0.77 | RECQL (0.42) | USP2SMN1; SMN2RECQLSETD7HSD17B10 | |
| SCHEMBL12078427 | 0.77 | RECQL (0.42) | USP2SMN1; SMN2RECQLSETD7HSD17B10 | |
| SCHEMBL12090269 | 0.77 | RECQL (0.42) | USP2SMN1; SMN2RECQLSETD7HSD17B10 | |
| SCHEMBL17395 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2RECQLPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | USP2 1834/4885SMN1; SMN2 4413/4885RECQL 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.